Overview
Blueprint Medicines Corporation, based in the United States, operates primarily in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of precision therapies for genetically defined diseases. Since its inception, Blueprint Medicines has built a robust portfolio of targeted therapies. One of its prominent projects includes the development of novel kinase inhibitors that are designed to selectively target underlying genetic drivers present in various malignancies and rare diseases. A notable achievement is the FDA approval of their therapies for gastrointestinal stromal tumors and advanced systemic mastocytosis. The firm's strategic execution in research and development strongly positions it as a leader in precision medicine, catering to previously underserved patient populations.
AI+ Ask Fintel’s AI assistant about Blueprint Medicines Corporation.
Thinking about good questions…
Basic Stats
The share price of Blueprint Medicines Corporation as of July 17, 2025 is $129.46 / share.
The Factor Analysis chart (below right) shows a view of Blueprint Medicines Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.50 |
| Beta | 0.77 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Blueprint Medicines Corporation is $132.96. The forecasts range from a low of $130.29 to a high of $141.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Blueprint Medicines Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-23 | Barclays | Equal-Weight | Maintains | |
| 2023-01-27 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-01-03 | Wells Fargo | Underweight | Equal-Weight | Upgrade |
| 2022-12-14 | Needham | Buy | Initiate | |
| 2022-12-12 | Barclays | Equal-Weight | Maintains | |
| 2022-11-04 | JMP Securities | Market Outperform | Maintains | |
| 2022-11-03 | Goldman Sachs | Buy | Maintains | |
| 2022-11-02 | Wedbush | Outperform | Maintains | |
| 2022-11-02 | SVB Leerink | Market Perform | Maintains | |
| 2022-11-02 | Oppenheimer | Outperform | Perform | Downgrade |
| 2022-11-02 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-11-02 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-11-02 | Barclays | Equal-Weight | Maintains | |
| 2022-09-14 | Berenberg | Buy | Initiate | |
| 2022-09-09 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-09-06 | Oppenheimer | Outperform | Maintains | |
| 2022-08-22 | Jefferies | Buy | Maintains | |
| 2022-08-18 | SVB Leerink | Market Perform | Maintains | |
| 2022-08-18 | Stifel | Buy | Maintains | |
| 2022-08-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-08-03 | SVB Leerink | Market Perform | Maintains | |
| 2022-08-03 | Raymond James | Strong Buy | Maintains | |
| 2022-08-03 | Goldman Sachs | Buy | Maintains | |
| 2022-07-08 | Oppenheimer | Outperform | Initiate | |
| 2022-07-01 | SVB Leerink | Market Perform | Maintains | |
| 2022-06-27 | Wells Fargo | Underweight | Initiate | |
| 2022-06-14 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-06-13 | SVB Leerink | Market Perform | Maintains | |
| 2022-06-10 | Citigroup | Neutral | Sell | Downgrade |
| 2022-06-01 | Jefferies | Hold | Buy | Upgrade |
| 2022-05-19 | Piper Sandler | Neutral | Maintains | |
| 2022-04-13 | Citigroup | Neutral | Maintains | |
| 2022-03-04 | Stifel | Buy | Maintains | |
| 2022-03-01 | Citigroup | Neutral | Initiate | |
| 2022-02-17 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2022-02-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-02-01 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-01-25 | Stifel | Hold | Buy | Upgrade |
| 2022-01-12 | SVB Leerink | Outperform | Maintains | |
| 2021-11-10 | Raymond James | Strong Buy | Maintains | |
| 2021-10-29 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-07-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-06-17 | Wedbush | Outperform | Maintains | |
| 2021-06-17 | SVB Leerink | Outperform | Maintains | |
| 2021-06-17 | Baird | Outperform | Maintains | |
| 2021-04-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-04-13 | Wedbush | Outperform | Maintains | |
| 2021-03-31 | Credit Suisse | Neutral | Initiate | |
| 2021-02-18 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-02-18 | Barclays | Equal-Weight | Maintains | |
| 2021-01-12 | SVB Leerink | Outperform | Maintains | |
| 2020-12-03 | Stifel | Hold | Initiate | |
| 2020-11-02 | Jefferies | Buy | Hold | Downgrade |
| 2020-10-30 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2020-10-16 | Raymond James | Strong Buy | Maintains | |
| 2020-10-13 | Morgan Stanley | Overweight | Maintains | |
| 2020-07-27 | SVB Leerink | Outperform | Maintains | |
| 2020-07-15 | SVB Leerink | Outperform | Maintains | |
| 2020-07-15 | Morgan Stanley | Overweight | Maintains | |
| 2020-07-15 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-06-08 | Deutsche Bank | Buy | Maintains | |
| 2020-05-05 | Barclays | Equal-Weight | Initiate | |
| 2020-04-30 | Morgan Stanley | Overweight | Maintains | |
| 2020-04-30 | Canaccord Genuity | Buy | Maintains | |
| 2020-04-29 | SVB Leerink | Outperform | Maintains | |
| 2020-04-29 | JMP Securities | Market Outperform | Maintains | |
| 2020-04-29 | HC Wainwright & Co. | Buy | Reiterate | |
| 2020-04-29 | BMO Capital | Outperform | Maintains | |
| 2020-03-17 | Deutsche Bank | Hold | Buy | Upgrade |
| 2020-03-17 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2020-02-18 | Morgan Stanley | Overweight | Maintains | |
| 2020-01-28 | BMO Capital | Market Perform | Initiate | |
| 2019-12-10 | Deutsche Bank | Hold | Maintains | |
| 2019-11-06 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2019-11-06 | Morgan Stanley | Overweight | Maintains | |
| 2019-10-29 | Deutsche Bank | Buy | Hold | Downgrade |
| 2019-10-11 | Morgan Stanley | Overweight | Maintains | |
| 2019-10-03 | H.C. Wainwright | Buy | Initiate | |
| 2019-09-12 | Raymond James | Market Perform | Outperform | Upgrade |
| 2019-08-29 | Piper Jaffray | Neutral | Initiate | |
| 2019-07-19 | Baird | Outperform | Initiate | |
| 2019-07-18 | Deutsche Bank | Buy | Initiate | |
| 2019-04-03 | Morgan Stanley | Overweight | Initiate | |
| 2018-09-25 | Leerink Swann | Outperform | Initiate | |
| 2018-06-04 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2018-04-16 | Wedbush | Outperform | Outperform | Maintains |
| 2017-10-23 | Morgan Stanley | Overweight | Maintains | |
| 2017-09-29 | DA Davidson | Buy | Initiate | |
| 2017-09-20 | Canaccord Genuity | Buy | Maintains | |
| 2017-08-03 | Canaccord Genuity | Buy | Maintains | |
| 2017-03-13 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2017-02-15 | Morgan Stanley | Overweight | Initiate | |
| 2016-08-05 | Canaccord Genuity | Buy | Initiate | |
| 2016-05-27 | Raymond James | Outperform | Initiate | |
| 2016-03-09 | JMP Securities | Market Outperform | Maintains | |
| 2015-05-26 | Wedbush | Outperform | Initiate | |
| 2015-05-26 | JMP Securities | Market Outperform | Initiate | |
| 2015-05-26 | Cowen & Co. | Outperform | Initiate | |
| 2023-02-06 | JMP Securities | Market Outperform | Reiterate | |
| 2023-02-14 | Needham | Buy | Reiterate | |
| 2023-02-10 | Needham | Buy | Reiterate | |
| 2023-02-17 | Raymond James | Strong Buy | Maintains | |
| 2023-02-17 | Needham | Buy | Maintains | |
| 2023-02-17 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-16 | Needham | Buy | Reiterate | |
| 2023-02-24 | SVB Leerink | Market Perform | Maintains | |
| 2023-02-27 | Needham | Buy | Reiterate | |
| 2023-02-28 | JMP Securities | Market Perform | Reiterate | |
| 2023-02-28 | Needham | Buy | Reiterate | |
| 2023-02-28 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-03-30 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-05 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-05-05 | Needham | Buy | Maintains | |
| 2023-04-19 | Needham | Buy | Reiterate | |
| 2023-05-23 | Guggenheim | Buy | Maintains | |
| 2023-05-23 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-23 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-05-23 | Wedbush | Outperform | Outperform | Reiterate |
| 2023-05-23 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-05-23 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-05-23 | Needham | Buy | Buy | Maintains |
| 2023-05-05 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-06-05 | SVB Leerink | Market Perform | Underperform | Downgrade |
| 2023-06-14 | Wells Fargo | Equal-Weight | Maintains | |
| 2024-05-03 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-05-03 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-05-03 | Needham | Buy | Buy | Maintains |
| 2023-10-27 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-10-27 | Oppenheimer | Perform | Outperform | Upgrade |
| 2023-10-27 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-10-27 | Needham | Buy | Buy | Maintains |
| 2023-08-02 | Needham | Buy | Buy | Reiterate |
| 2023-08-21 | Needham | Buy | Buy | Maintains |
| 2023-07-31 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2024-05-03 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-02 | Needham | Buy | Buy | Reiterate |
| 2023-08-07 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-12-22 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2023-12-19 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-02-16 | Citigroup | Sell | Sell | Maintains |
| 2024-02-16 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-08-03 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-08-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-03 | Needham | Buy | Buy | Reiterate |
| 2023-08-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-07-14 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2024-01-16 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-04-26 | Stifel | Buy | Buy | Maintains |
| 2024-04-26 | Wedbush | Outperform | Outperform | Reiterate |
| 2024-04-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-26 | Needham | Buy | Buy | Reiterate |
| 2023-12-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-14 | Stephens & Co. | Overweight | Initiate | |
| 2024-05-06 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-05-06 | Leerink Partners | Underperform | Market Perform | Upgrade |
| 2024-02-26 | Needham | Buy | Buy | Reiterate |
| 2024-04-10 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-02-13 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-05-03 | Citigroup | Sell | Sell | Maintains |
| 2024-05-03 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-06-07 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-01-09 | Stifel | Buy | Buy | Maintains |
| 2024-06-28 | Needham | Buy | Buy | Reiterate |
| 2024-07-08 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-07-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-01 | Needham | Buy | Buy | Reiterate |
| 2025-01-27 | Piper Sandler | Neutral | Neutral | Maintains |
| 2025-06-04 | Citigroup | Sell | Neutral | Upgrade |
| 2024-08-05 | Needham | Buy | Buy | Maintains |
| 2025-02-13 | Needham | Buy | Buy | Reiterate |
| 2024-11-14 | JP Morgan | Overweight | Initiate | |
| 2024-10-31 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-02-04 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-10-31 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-31 | Needham | Buy | Buy | Maintains |
| 2025-01-15 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-10-30 | Needham | Buy | Buy | Reiterate |
| 2025-02-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-15 | Needham | Buy | Buy | Reiterate |
| 2024-07-29 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-02 | Guggenheim | Buy | Buy | Maintains |
| 2024-08-02 | Baird | Outperform | Outperform | Maintains |
| 2025-04-16 | Wedbush | Outperform | Outperform | Reiterate |
| 2025-03-17 | Jefferies | Buy | Initiate | |
| 2024-11-18 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-12-09 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-10-24 | UBS | Neutral | Initiate | |
| 2025-02-14 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-02-14 | Needham | Buy | Buy | Reiterate |
| 2025-01-13 | Needham | Buy | Buy | Reiterate |
| 2025-04-08 | Needham | Buy | Buy | Reiterate |
| 2025-01-13 | Wedbush | Outperform | Outperform | Reiterate |
| 2025-01-02 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-03-03 | Citizens Capital Markets | Market Outperform | Market Outperform | Reiterate |
| 2025-03-07 | Scotiabank | Sector Outperform | Initiate | |
| 2024-12-11 | Guggenheim | Buy | Buy | Reiterate |
| 2025-05-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-02 | JP Morgan | Overweight | Neutral | Downgrade |
| 2025-06-02 | Scotiabank | Sector Outperform | Sector Perform | Downgrade |
| 2025-06-02 | Needham | Buy | Hold | Downgrade |
| 2025-06-02 | Wedbush | Outperform | Neutral | Downgrade |
| 2025-04-28 | Needham | Buy | Buy | Maintains |
| 2025-06-03 | Wolfe Research | Outperform | Peer Perform | Downgrade |
| 2025-06-03 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2025-06-05 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-06-05 | UBS | Neutral | Neutral | Maintains |
| 2025-06-17 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2025-06-03 | JMP Securities | Market Outperform | Market Perform | Downgrade |
